Effect of Inspiratory Muscle Training on Pain in Patients With Knee Osteoarthritis: A Randomized Controlled Trial
| Registry | NCT07698418 |
|---|---|
| Status | Not yet recruiting |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: triple, treatment |
| Enrollment | 80 (Estimated) |
| Sponsor | The Hong Kong Polytechnic University (Other); collaborators: Zunyi Medical College |
| Conditions | Knee Osteoarthritis, Knee Osteoarthritis (Knee OA) |
| Interventions | Inspiratory muscle training, Sham inspiratory muscle training (Other) |
| Dates | start 2026-09-01 (estimated), primary completion 2030-09-01 (estimated), completion 2030-09-01 (estimated), first posted 2026-07-13, last updated 2026-07-16 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Knee Osteoarthritis All trials for Knee Osteoarthritis (Knee OA) All trials of Inspiratory muscle training All trials of Sham inspiratory muscle training
Knee osteoarthritis (KOA) is a common joint disease that causes chronic pain and limits daily activities. Current treatments, such as painkillers or surgery, have limitations like side effects or high costs. This study will test whether a safe, non-drug intervention-inspiratory muscle training (breathing exercises against resistance)-can reduce knee pain in people with KOA. The training may work by lowering inflammation and improving the brain's modulation of pain.
Eighty patients aged ≥55 years with confirmed KOA and frequent knee pain will be enrolled. Participants will be randomly assigned to either an 8-week inspiratory muscle training program (5 sessions per week, with gradually increasing resistance) or a sham (very low resistance) training program. Neither the patients nor the researchers assessing the outcomes will know who is in which group.
The main outcome is change in knee pain measured by a visual analog scale (VAS). Secondary outcomes include blood markers of inflammation (TNF-α, IL-6, IL1β), physical function, the Knee injury and Osteoarthritis Outcome Score (KOOS), inspiratory muscle strength, activity level, sleep quality, and quality of life. To explore underlying mechanisms, outcomes included heart rate variability (HRV) as an indicator of autonomic nervous system function, and brain functional connectivity in the prefrontal cortex using functional near-infrared spectroscopy (fNIRS) are collected. These mechanistic assessments will be performed at baseline and at the end of 8-week intervention. Additional follow-up assessments for clinical outcomes will be done at 3 and 6 months after the training ends. Any side effects or adverse events will be recorded.
This study will provide high-quality evidence on whether inspiratory muscle training is an effective and safe complementary treatment for knee pain in people with knee OA, and will offer new insights into the mechanisms underlying its analgesic effects.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Inspiratory Muscle Training | Experimental | Other: Inspiratory muscle training | 5 sessions/week for 8 weeks. Load starts at 50% MIP for 40 reps, increases to 80% MIP for 60 reps from week 5, then adjusted weekly to 80% of updated MIP. Device: threshold inspiratory muscle trainer. |
| Sham Inspiratory Muscle Training | Sham comparator | Other: Sham inspiratory muscle training | Participants perform sham inspiratory muscle training with the same frequency and duration as the experimental group, but the inspiratory load is fixed at 10% of maximal inspiratory pressure (MIP) and does not progress. All other procedures (weekly MIP measurement for sham load adjustment) are identical to maintain blinding. |
Sex: All, ages: 55 Years to 80 Years
Inclusion Criteria: * Aged 55 years or older. * Knee osteoarthritis (Kellgren-Lawrence grade ≥ 2). * Knee pain (Visual Analogue Scale, VAS ≥ 3) on the most days in the past month. * Able to walk independently without assitive devices. Exclusion Criteria: * History of knee replacement surgery, meniscus surgery, or ligament surgery. * Received corticosteroid injection within the previous three weeks. * Diagnosed with rheumatoid arthritis. * Unstable angina, recent myocardial infarction, uncontrolled cardiac arrhythmia, or severe heart failure. * History of stroke. * Currently receiving steroid therapy, hormonal therapy, or cancer chemotherapy. * Pneumothorax, pulmonary bullae, lung surgery within the past 12 months, unstable asthma, or severe dyspnea at rest. * Unable to understand the study procedures and potential risks.